Coreg and Excessive granulation tissue - a phase IV clinical study of FDA data

Summary:

Excessive granulation tissue is reported as a side effect among people who take Coreg (carvedilol), especially for people who are female, 40-49 old, also take Zometa, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Excessive granulation tissue when taking Coreg. It is created by eHealthMe based on reports of 48,155 people who have side effects when taking Coreg from the FDA, and is updated regularly.

What is Coreg?

Coreg has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 49,583 Coreg users. Check the latest studies of Coreg.

What is Excessive granulation tissue?

Excessive granulation tissue (excessive collagen-rich tissue which forms at the site of an injury) is found to be associated with 393 drugs and 286 conditions by eHealthMe. Check the latest studies of Excessive granulation tissue.

On Jul, 13, 2026

48,155 people reported to have side effects when taking Coreg.
Among them, 35 people (0.07%) have Excessive granulation tissue.

Could Coreg cause Excessive granulation tissue?

Among these 35 people:

What is the gender of people who have Excessive granulation tissue when taking Coreg? *

female: 97.14 %
male: 2.86 %

What is the age of people who have Excessive granulation tissue when taking Coreg? *

What are other drugs people take besides Coreg? *

What are other side effects people have besides Excessive granulation tissue? *

Bone Disorder: 34 people, 97.14%
Bone Fragmentation: 32 people, 91.43%
Loose Tooth: 32 people, 91.43%
Tooth Disorder (tooth disease): 32 people, 91.43%
Pain In Jaw: 32 people, 91.43%
Pain: 31 people, 88.57%
Acute Kidney Failure: 27 people, 77.14%
Anaemia (lack of blood): 26 people, 74.29%
Constipation: 26 people, 74.29%
Inflammation: 25 people, 71.43%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 24 people, 68.57%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 21 people, 60.00%
Fatigue (feeling of tiredness): 21 people, 60.00%
Breast Cancer: 10 people, 28.57%
Metastases To Bone (cancer spreads to bone): 9 people, 25.71%
Breast Cancer Metastatic: 9 people, 25.71%
Hyperthyroidism (over activity of the thyroid gland): 1 person, 2.86%
Cardiac Failure Congestive: 1 person, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Coreg and have Excessive granulation tissue?

- Check whether Excessive granulation tissue is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Coreg:

Coreg (49,583 reports)

Browse all side effects of Coreg:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Excessive granulation tissue:

Excessive granulation tissue (393 drugs)

Browse all the conditions that are associated with Excessive granulation tissue:

Excessive granulation tissue (286 conditions)

Related publications that referenced our studies

Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .
Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on carvedilol (the active ingredients of Coreg) and Coreg (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.